ICU Earning Date, Earning Analysis and Earning Prediction

Quarterly Results

ICU Earnings Forecast

Looking ahead, ICU remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2026/Q1 project quarter revenue of 375.00K and an EPS of -0.11.

However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been unchanged by 0%, while EPS estimates have been unchanged by 0%. For the upcoming Q4 2025, revenue estimates have been adjusted unchanged by 0%. These revisions correlate with a 46.88% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in ICU long-term fundamentals.

The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

RevenueEPS

Currency: USD

Revenue Estimate-:0

EPS Estimate-:0

—

Stock Price0

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Revenue Estimates for Q4 2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+46.88%

In Past 3 Month

Earnings Forecast

Revenue

EPS

Currency: USD

Actual

Estimate

AI Analysis

Earnings Surprise Analysis

Revenue

EPS

AI Analysis

Earnings Reaction

The chart below shows how ICU performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ICU sees a 10.02% change in stock price 10 days leading up to the earnings, and a -6.04% change 10 days following the report. On the earnings day itself, the stock moves by -1.82%. This data can give you a slight idea of what to expect for the next quarter's release.

For example, in DEC/2025, the stock changed 22.37% on the day following the earnings release and then changed by 54.61% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

People Also Watch

Frequently Asked Questions

What were the key highlights of ICU's latest earnings report for ?

ICU reported its earnings on 2026-03-25, showcasing a revenue of 420.00K against an estimate of 500.00K, resulting in a -16% surprise. The EPS was -0.8, surpassing the expected -0.97 by 17.53%. The stock experienced a 22.37% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

How did ICU's stock price react after the earnings release?

Following ICU's earnings announcement on 2026-03-25, the stock price moved by 22.37% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, ICU's stock price tends to shift by an average of 10.02% in the 10 days leading up to earnings and -6.04% in the 10 days following, providing insight into potential market.

What are the revenue and EPS estimates for ICU for 2026/Q1?

For 2026/Q1, analysts estimate ICU's annual revenue to reach 375.00K, while the EPS is projected at -0.11. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

How does ICU's stock price correlate with earnings forecast revisions?

The correlation between ICU's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

What should investors expect from ICU's next earnings report?

Based on historical trends, ICU's stock price typically moves by 10.02% in the 10 days before its earnings and -6.04% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.11 and revenue of 375.00K.

What is the sentiment in SeaStar Medical Holding Corp (ICU) Q1 2025 Earnings Call Summary?

The earnings call highlights a fourfold revenue increase and a significant reduction in net loss, suggesting improved financial performance. The company is expanding its market presence with QUELIMMUNE and has a substantial market opportunity in adult AKI. Despite some regulatory and competitive risks, the management's optimistic outlook on faster approvals and pipeline growth is encouraging. The Q&A session revealed active engagement in clinical trials and expansion in pediatric sites, supporting a positive sentiment. Overall, the financial improvements and strategic positioning point to a potential 2% to 8% stock price increase.